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Natural product modulators of transient
receptor potential (TRP) channels as potential
anti-cancer agents
Tiago Rodrigues,a Florian Sieglitza and Gonçalo J. L. Bernardes*ab
Treatment of cancer is a significant challenge in clinical medicine, and its research is a top priority in
chemical biology and drug discovery. Consequently, there is an urgent need for identifying innovative
chemotypes capable of modulating unexploited drug targets. The transient receptor potential (TRPs)
channels persist scarcely explored as targets, despite intervening in a plethora of pathophysiological
events in numerous diseases, including cancer. Both agonists and antagonists have proven capable of
evoking phenotype changes leading to either cell death or reduced cell migration. Among these, natural
products entail biologically pre-validated and privileged architectures for TRP recognition. Furthermore,
several natural products have significantly contributed to our current knowledge on TRP biology. In this
Tutorial Review we focus on selected natural products, e.g. capsaicinoids, cannabinoids and terpenes, by
highlighting challenges and opportunities in their use as starting points for designing natural product-
inspired TRP channel modulators. Importantly, the de-orphanization of natural products as TRP channel
ligands may leverage their exploration as viable strategy for developing anticancer therapies. Finally, we
foresee that TRP channels may be explored for the selective pharmacodelivery of cytotoxic payloads to
diseased tissues, providing an innovative platform in chemical biology and molecular medicine.
Key learning points
(1) Transient receptor potential (TRP) channel modulation as a strategy for cancer cell killing.
(2) Natural products are privileged chemical matter for TRP modulation.
(3) Natural products may be promiscuous multi-TRP channel modulators.
(4) TRP modulators may be used to vectorize cytotoxic payloads.
1. Introduction
Cancer remains a leading cause of death and morbidity worldwide,
despite extensive basic and clinical research efforts dedicated to
finding ways to control tumour growth and cure diseased tissues.
Typically, anti-cancer small molecules aim to selectively modulate
crucial and often up-regulated drug targets and signalling
pathways. However, the rapid evolution of resistance in tumour
cells to the current therapeutic armamentarium poses a great
challenge to the design of effective long-term chemotherapeutic
schemes and prototypes for sustained personalized medicines.1,2
Thus, innovative chemotypes capable of modulating unexplored
cancer-relevant targets are constantly sought for.
Such targets, amongst others, involve signals elicited by the
intracellular second messenger calcium (Ca2+). It is well established
that cytosolic free Ca2+ acts as a key regulator of fundamental down-
stream processes in cancer, including proliferation, differentiation,
and gene transcription.3,4 As a result, Ca2+ influx remodelling
may disrupt intracellular pathophysiological events and induce
cancer cell death.3
Transient receptor potential (TRP) cation channels encompass
six different subfamilies that control Mg2+/Ca2+ homeostasis,
including the vanilloid (TRPV), melastatin (TRPM), canonical
(TRPC), ankyrin (TRPA), mucolipin (TRPML), and polycystic
(TRPP).5 While technical challenges on both NMR spectroscopy
and X-ray crystallography have generally proven insurmountable
for obtaining structural data, information on domain composition
has been primarily gained through in silico modelling and
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structure–function relationship studies. More recently, break-
through cryo-electron microscopy structures of the mammalian
TRPV1 have provided critical insights on a dual gating mechanism
for ion transport.6,7 Furthermore, allosteric coupling between
the upper and lower gates rationalize the finely controlled
channel dynamics,6,7 and reveal opportunities for future drug
discovery endeavours. Typically, TRP channels are comprised by
six transmembrane-spanning domains (S1–S6), a pore-forming
loop between S5 and S6, and assemble as homo- or hetero-tetramers
(Fig. 1a–c). TRP channels are widely distributed in diverse tissues.8
Moreover, together with accessory proteins, they mediate a plethora
of cellular processes. Surprisingly, TRP channels have seldom
been investigated as drug targets, despite their ‘‘druggability’’
and relevance to a multitude of pathologies.5 For example,
only 4 of the 28 mammalian TRP counterparts have yielded
clinical stage ligands to date, primarily as analgesic agents.9
The (patho)physiology associated to TRP channels, i.e. channelo-
pathies, and the deorphanization of TRP channels with natural
products have already been extensively reviewed elsewhere.5,10,11 In
this Tutorial Review we focus on how TRP channels are attractive
drug targets per se or for the targeted delivery of cytotoxic payloads.
We provide a selection of prototypical natural products and
derivatives with anti-cancer activity partly or fully related to TRP
engagement. Special attention is given to chemical matter
modulating the TRPV, TRPM and TRPC channels, including
future implications in cancer drug discovery.
2. Transient receptor potential
channels in cancer
The role of TRP channels in cancer is highly heterogeneous,
ranging from the control of Ca2+ homeostasis to regulation of
tumourigenic and metastatic events. Tumour progression can
be generally associated with misregulation of either one or
more TRP channels.4 Though, as Gkika and co-workers8 point
out, a full expression profiling of these channels is still required
in order to correlate a cancer-specific pattern to carcinogenesis
staging. Furthermore, several members of the TRP channel
family are highly expressed in normal tissues while for many
others thorough expression profiles, e.g. on a cellular level, are
lacking. For example, TRPC4 is found in brain, bone, heart and
prostate, whereas TRPM1-3 are highly expressed in brain tissue.5,8
Thus, the advantages of targeting TRP channels in cancer must
be carefully traded off against possible adverse reactions in
other tissues. Interestingly, the role of TRP channels appears
to be dependent on the cell type, i.e. a given channel may be
either oncogenic or tumour suppressive in different cancers.
TRPV2 presents a perfect example. On one hand it is over-
expressed and required for invasiveness of metastatic prostate
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adenocarcinoma. On the other hand, its overexpression inhibits
growth of glioblastoma.5
TRPV1 and TRPV6 rank among the most studied channels in
cancer. Studies on clinical samples have shown that TRPV6 is
overexpressed in most prostate cancers and thus can be generally
used as a marker to predict clinical outcomes.12
TRPM8 channels constitute some of the most studied counter-
parts within the melastatin channel family. Its widespread over-
expression in many prostate, breast, colon, lung and skin tumours,
in opposition to low or undetectable levels in the corresponding
normal tissues, make it an attractive target for cancer modulation.13
Moreover, TRPM8 may be effectively used in prostate cancer
diagnosis and staging.14 Among the TRPC subfamily, it has been
reported that expression and activation of TRPC1 decreases Ca2+-
dependent apoptosis and cancer progression in the neuroblastoma
SH-SY5Y cell line.15 Furthermore, together with TRPC6 it mediates
Ca2+ signalling in MCF7 breast cancer cells.16 TRPC6 may
simultaneously have an important role in most liver and gastric
cancers given its up/mis-regulation in tumourigenic tissues.17,18
Finally, activation of TRPC4/5 was recently unveiled to induce
death in the renal cell carcinoma A498 cell line via high Ca2+
influx and overload.19,20
Taken together, a deeper understanding of TRP channel
biology in diverse cancer cell-lines promises a new window of
opportunity for developing innovative anti-cancer agents. While
blockage of cancer-relevant drug targets has been a better-
established concept for developing therapeutic agents and
tackling tumours, promotion of the TRP-mediated Ca2+ influx
for intracellular Ca2+ overload is not only toxic to cells, but also
attainable and effective19 (Fig. 2). Hence, modulation of TRP
Fig. 1 (a) Schematics of TRP channel subfamilies and domain organization. (b) General overview of TRPV channels exemplified by the TRPV1 atomic
model (PDB 3J5Q); (c) focus on the Pore-S6 domain of TRPV1. Images generated with PyMOL (Schrödinger LLC).
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channels offers a much-sought opportunity for unravelling
drug-relevant chemical space, while exploiting innovative and
presumably intellectual property-free chemotypes. Moreover,
the evolutionary sequence similarity between these channels5
provides a solid basis to consider promiscuous target engagement
profiles by TRP ligands and tight integration of TRP channels in
diverse polypharmacology networks. Nevertheless, considering the
heterogeneous expression of TRPs in diverse cancers, its ligands
may be best employed in personalized medicine schemes.
3. Natural product modulators of TRP
channels
Natural products have long been a valuable source of chemical
matter for interrogating biological systems, while acting as
biologically pre-validated prototypes for chemical probe and
drug discovery. Such role has been especially prominent in anti-
cancer research with ca. 50% of FDA-approved drugs since 1940
being either natural products or their derivatives.21 Thus, it
is widely accepted that the intricate architectures generally
comprised in natural products offer a multitude of opportunities
for exploring drug-relevant chemical space only sparingly covered
by synthetic small molecules. In particular, deorphanisation of
TRP channels by natural product ligands11 has, together with
knock-down/knock-out studies, contributed to the understanding
of the gating mechanism and function for this ion channel
family.11 Moreover, the discovery of natural product modulators
of TRP channels has led to the development of mimics as chemical
probes and drug leads.11
On- and off-targets remain largely unknown for the majority
of naturally occurring chemotypes, hindering the use of rational
approaches to design natural product-inspired chemical entities.22
While proteomics is the technology of choice for identifying
macromolecular binding counterparts, target prediction software
tools have increasingly proven useful for that purpose.22,23 In fact,
from a pharmacophore feature pair point of view, the ligand-based
software SPiDER24 suggests that a significant proportion of natural
products annotated in the Dictionary of Natural Products database
display potential pharmacophores for modulation of one or
more TRP channels.22 Hence, although experimental confirmation
is required for said predictions, the data advocates that natural
products present privileged scaffolds for engaging TRP ion channels.
Given that several of these compounds theoretically present
‘‘pathological’’ moieties, i.e. substructural motifs commonly
flagged for promiscuous unspecific binding, it will be imperative
to validate TRP channel screening hits by assessing their potential
to form colloidal aggregates, and counter screen them in orthogonal
assays and/or against unrelated proteins.
3.1 TRPV modulators
TRPV1 remains the most studied receptor within the TRP channel
family and is important for nociception. It can be activated by a
wide range of stimuli amongst them heat, low pH, allyl isothio-
cyanate, N-oleyl-dopamine and vanilloids.5 Its prototypical and
best studied ligand capsaicin (Fig. 3) is a natural product isolated
from Capsicum spp. (i.e. ‘‘hot’’ chilli pepper), which potently
mediates intracellular Ca2+ influx (EC50 = 40 nM). Recent cryo-
electron microscopy data,6,7 together with computational modelling
and mutagenesis studies,25 provide solid evidence of the molecular
mechanisms of TRPV1 activation. Capsaicin sits in an intracellular
binding site26 in a ‘‘tail-up, head-down’’ configuration. While the
vanillyl and amide moieties establish directed interactions to anchor
its binding position, the flexible hydrophobic tail may adopt
several bioactive conformations and mediate hydrophobic contacts
within the receptor.25
Fig. 2 Modulation of TRP channels with agonists induces intracellular Ca2+ overload, with subsequent cell death.
Fig. 3 Chemical structure of selected TRPV1 natural product agonists
with anticancer activity.
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Recognition of the importance of TRPV1 and putative ligands
in cancer progression has spurred interest in their exploitation
as potential drug lead candidates. The TRPV1-dependent increase
of intracellular reactive oxygen species (ROS) endorsed by capsaicin
is known to inhibit cancer progression.27 Considering that
experimental conditions often include capsaicin at concentrations
several orders of magnitude higher than required for TRPV1
activation, it comes at no surprise that several mechanisms and
signalling pathways, from off-target engagement, interplay in
phenotype changes. In fact, it has been realized that capsaicin-
induced cell death is mediated by TRPV1 at low doses in a
variety of cancer cell lines, whereas TRPV1-independent effects
take over from high dose and prolonged exposure.28 Interestingly,
capsaicin equally promotes the production of ROS through
TRPV1-independent pathways.29 Without evidence of a clear
mechanism of action, 10 mM capsaicin causes G0/G1 cell-cycle
arrest in ER-positive and negative breast carcinoma variants,
further contributing to confounding effects.30 The anti-proliferative
effects of capsaicin against the androgen-sensitive PC-3 prostate
cancer cells proceed via a TRPV1-dependent pathway and the
increase of intracellular Ca2+ concentration is responsible for
apoptosis.31
Malignant gliomas are one of the most aggressive and thera-
peutically challenging cancer types. Whereas important progresses
in the understanding of relevant pathobiology and medicinal
chemistry have been made in the past decade, innovative
therapies are still urgently required.5 Amantini et al. have
shown TRPV1-dependent apoptosis of U373 glioma cells (grade
III), involving Ca2+ influx, p38 MAPK activation, mitochondrial
transmembrane potential dissipation and Caspase-3 activation
at capsaicin concentrations ranging from 1–50 mM.28 Importantly,
oral administration of 2.5–5 mg kg1 capsaicin is able to
significantly reduce growth of pancreatic tumour xenografts
in mice without any reported side effects.27 However, contradictory
studies report capsaicin induced up-regulation of tumour associated
NADPH oxidase in colon carcinoma cells promoting proliferation
and migration32 as well as enhanced invasiveness of colorectal
cancer cells upon capsaicin treatment due to induction of
Matrixmetalloprotease-2 and -9.33 Taken this into account as
well as the broad expression of TRPV1 in various tissues, carefully
planned studies will have to show if capsaicin-inspired small
molecules may find applicability in early drug discovery programs.
Natural products structurally related to capsaicin are commonly
labelled as capsaicinoids. In general, these share the vanillin head
coupled to a hydrophobic tail of varying lengths and topologies.
One such example, piperine, activates moderately TRPV1 (EC50 =
38 mM) and produces cell cycle arrest of human prostate cancer
PC3 and LNCaP cell lines.34 In similar fashion to capsaicin, it
induces production of ROS, loss of mitochondrial membrane
integrity, caspase and p38 MAPK activation,35 suggesting the
relevance of TRPV1 for the observed functional effects. In
particular, 75–150 mM of piperine was shown to selectively
inhibit growth of several colon cancer cell lines.35 6-Gingerol
is a major component of ginger and a single-digit micromolar
agonist of TRPV1 that significantly affects cell viability of the HeLa
and LoVo cancer cell lines, by increasing the level of ROS.36
6-Shogaol is a potent agonist of TRPV1 channels with an EC50
value of ca. 770 nM. Intracellular Ca2+ is not only rapidly
increased during 6-shogaol-mediated TRPV1 activation, but
also reversible upon wash out of the natural product. Hence, data
suggests that a lipophilic surrogate, i.e. similar pharmacophore
features, may substitute the Michael acceptor in the hydrophobic
tail of 6-shogaol without sacrificing bioactivity.37 Interestingly, it
was recently reported the anti-cancer activity of 6-shogaol at TRPV1
activation-relevant concentrations against breast carcinoma cell
lines. Though, it remains unknown whether the engagement of
TRPV1 channels is responsible for the cytotoxicity or not.38
Resiniferatoxin is a diterpene-based natural product with
high affinity (KD = 25–480 pM) and potent agonist activity in
TRPV1 channels (EC50 = 1 nM).
39 Cryo-electron microscopy data
shows that resiniferatoxin sits in an overlapping, yet non-identical
binding site to capsaicin.7 Like other TRPV1 agonists, it induces
apoptosis in several bladder cancer cell lines by modulating
mitochondrial function, depolarization and increase of ROS
production at ca. 20 mM. However, data also advocates that the
observed effects are TRPV1-independent, thus supporting a
promiscuous profile by the natural product at high concentrations.
Xenograft mouse models of bladder cancer have shown signifi-
cantly reduced tumour growth upon treatment with 10 mM
resiniferatoxin without detectable toxicity.40
In opposition to TRPV1, the osmo and mechano sensory
related TRPV2 is one of the least studied vanilloid receptors.
The absence of specific TRPV2-modulating chemical tools has
been causative for the current lack of knowledge on the under-
lying pharmacology. The only known ligand for TRPV2 is the
natural product cannabidiol (Fig. 4), which is a potent single-
digit micromolar agonist of TRPV2, yet targeting TRPA1 and
other cellular receptors as well. No selective antagonists have
been validated thus far.41
TRPV2 has been found overexpressed in a multitude of cancer
cell lines – human hepatocarcinoma cells (HepG2), bladder and
prostate cancers. Moreover, TRPV2 transcript levels seem to correlate
with the metastatic potential of prostate cancers.42 Introduction of
TRPV2 in the LNCaP prostate cancer cell line, enhances migration
and cancer progression, as it promotes the expression of invasion
markers such as Matrix metalloproteinase 9 and Cathepsin B. In line
with these observations, silencing of TRPV2 with siRNA reduces
tumour growth and invasiveness of TRPV2-expressing prostate
cancers.42 Consequently, effective blockage of TRPV2 channels
may offer an innovative means of inhibiting cancer metastases.
A large body of evidence supports the anticancer activity of
cannabidiol, whose putative targets further include the cannabinoid
receptor 2, serotonin 5-HT1A receptor, GPR55 and the peroxisome
Fig. 4 Chemical structure of the TRPV2 and TRPV4 agonists.
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proliferator-activated receptor gamma.43 In bladder cancer, 30 mM
cannabidiol was shown to lead to cell death through TRPV2-
mediated Ca2+ influx, suggesting the feasibility of activating
TRPV2 channels as therapeutic strategy.44 Interestingly, cannabidiol
may be additionally used to sensitize TRPV2-expressing glio-
blastoma cells to effectively promote the uptake of small cytotoxic
molecules (e.g. temozolomide, carmustine or doxorubicin) with
no effect in normal astrocytes. Although data from Santoni and
co-workers might indicate that cytotoxic drugs such as doxorubicin
can directly permeate through the pores of activated TRP channels,
such as TRPV1, TRPV2 or TRPM845 a validation of this mechanism
is still missing. Namely, it remains to be determined if the small
molecules enter the tumour cells directly through the TRP pores or
if the drug uptake is indirectly regulated through a yet unknown
mechanism that requires TRP-mediated Ca2+ signals to induce
sensitization. Indeed, Santoni and co-workers reported that
depletion of Ca2+ from the cell culture medium by EGTA blocks
small molecule uptake and cytotoxicity despite channel activation,
favouring the latter hypothesis. Being subject to industrial property
protection (US20100311678 A1), where several TRP channels
and respective agonists are foreseen to improve the uptake of
doxorubicin to cancer cells, research efforts have to be done to
unravel this promising mechanism.
Like for its congeners, the discovery of specific agonist and
antagonist small molecules for TRPV4 is bound to clarify its
roles in cancer and other (patho)physiological events.14,46 Fusi
et al. have provided evidence that TRPV4 mediates the release
of IL-8 in keratinocytes to limit cancer progression. Moreover,
exposure to the semi-synthetic diterpenoid agonist 4a-PDD
(EC50 = 200 nM, Fig. 4) elicits a concentration-dependent release
of IL-8,47 which may result in favourable therapeutic outcomes.
3.2 TRPM modulators
Regarding the TRPM subfamily most studies focused on either
TRPM7 or TRPM8. For instance, the expression of melastatin
TRPM8 in sensory neurons is required for cold sensation and
regulation of serum insulin levels.48 Similarly to TRPV1, pro-
longed agonist exposure to TRPM8 causes Ca2+ currents to adapt,
desensitizing stimulation. Here, increased Ca2+ influx subsequently
leads to cleavage of a membrane phospholipid – phosphati-
dylinositol 4,5-bisphosphate – which activates cellular down-
stream events to inactivate the channel. TRPM8 has been found
on several tissues, e.g. bladder, prostate, where it serves unknown
functions other than sensory. TRPM8 is dramatically over-
expressed in many prostate, breast, colon, lung and skin cancers,
suggesting its important roles in cancer.49 Importantly, menthol
(Fig. 5) is a prototypical TRPM8 terpene agonist with its ()
isomer being more potent than the (+) counterpart (EC50 = 4–80 mM)
in promoting cold sensation.50 TRPM8 ligands may equally find
potential application as probes or drug leads against cancerous
diseases.11 Exposure of melanoma cells to menthol down-regulates
TRPM8 expression dose-dependently and induces cell death
(IC50 = 12 mM).
51 As such, Dendreon Corp. developed a menthol-
inspired benzoimidazole (D-3263; Fig. 5) for the treatment of
prostatic hyperplasia and have recently conducted phase I clinical
trials on advanced solid tumours (clinicaltrials.gov identifier:
NCT00839631), exploring the therapeutic benefits of selective
Ca2+ overload in transformed cells. Cannabigerol (Fig. 5) is
a cannabinoid that potently blocks TRPM8 (IC50 = 0.11 
0.02 mM) while moderately activating TRPV1, TRPV2 and TRPA1
channels. It selectively inhibits growth of colon carcinoma cells
both in vitro and in xenograft models. In fact, the cannabigerol-
induced apoptosis is associated with ROS generation and is
independent from the activation of other TRP channels.52
Camphor (Fig. 5) is a known TRPM8 modulator that has been
linked with the arrest of keratinocyte proliferation through
activation of TRPV3 (WO/2014/078868).
Fingolimod (Fig. 5) is a derivative of myriocin, a fungal
metabolite of Isaria sinclairii, and an analogue of sphingosine.
Both fingolimod and sphingosine potently block TRPM7 with
IC50 values of 0.72 and 0.59 mM, respectively. Interestingly,
modulation of TRPM7 by fingolimod significantly alters both
HEK-293 cell migration and proliferation, and is in line with its
anticancer effect in vitro and in vivo. Considering the requirement
of TRPM7 activity for breast cancer cell metastasis, treatment with
fingolimod may deserve further attention.53
As seen from the cited examples, the confounding effects of
fragment-like natural products on TRP biology appear to be
commonplace. Hence, the phenotype change induced by such
molecules is generally best explained via multi-target engagement.
3.3 TRPC modulators
Although the exact role in cancer is yet to be determined, several
members of the TRPC subfamily are crucial for cancer proliferation,
as exemplified by experiments that employed siRNA-mediated gene
silencing. TRPC expression may be linked with cancer staging of
progressive cancers, offering a valid diagnostic marker.54,55 Recently,
the sesquiterpene agent ()-englerin A (Fig. 6) was identified as a
discriminative and nanomolar-potent TRPC4/5 agonist in renal cell
Fig. 5 Chemical structure of the TRPM7 and TRPM8 agonists.


























































































6136 | Chem. Soc. Rev., 2016, 45, 6130--6137 This journal is©The Royal Society of Chemistry 2016
carcinoma cell lines with moderate effects on other ion channels.19,20
Waldmann, Beech and co-workers determined that ()-englerin A
evoked Ca2+ entry rather than Ca2+ release from intracellular storages
with high effectiveness (IC50 ca. 10 nM). This Ca
2+ overload was
subsequently responsible for the potent anti-cancer-selective effects.
Data suggests that ()-englerin A has limited effect against TRPC6/
M2/V4 and engages reversibly a binding site of TRPC4 that is either
extracellular or only accessible from the external leaflet of the
membrane bilayer.19 Despite being a powerful chemical tool to
assess TRPC4/5 channels, the development of ()-englerin A
into an efficacious investigational anti-cancer drug candidate
may still prove challenging. In fact, pieces of evidence show that
oral administration of 5 mg kg1 to rats is well tolerated, but
insufficient blood exposure is achieved. On the other hand, a
single 1 mg kg1 intravenous administration results in immediate
animal death, while a 1.5 mg kg1 subcutaneous injection leads to
tolerable yet undetectable ()-englerin A exposure. Given the
narrow therapeutic window in mouse models, and the perceived
selectivity of ()-englerin A for TRPC4/5, it is possible that its
associated toxicity is linked to agonizing TRPC4/5 in diverse
tissues. Accordingly, further studies on TRPC4/5 biology are required
to validate their engagement benefits in anti-cancer therapy.20
Modulation of hitherto unknown off-targets by ()-englerin A
cannot be irrevocably neglected and biochemical validation of
these may shed light on complex systems biology networks.
4. Outlook
While natural products offer innovative scaffolds and viable
starting points for exploring chemical space relevant to TRP
channel biology, the latter continue under-explored in the chemical
biology and drug discovery contexts. Growing experimental
evidence suggests that TRP channels play a leading role in
cancer progression, and that disrupting Ca2+ homeostasis triggers
important cancer-cell phenotype changes. Some may be used
inclusively as biomarkers for tumour staging. Moreover, unlike
many other target families, both agonists and antagonists may
present clinical value.
With the advent of drug delivery systems and an impending
need to selectively deliver cytotoxic payloads to cancer cells,
TRP channels may become candidates for directing anti-cancer
drugs. To that end, it is relevant to: (i) understand the expression
patterns of these channels across all body tissues; (ii) identify high
affinity and selective TRP ligands for suitable vectorization of
cytotoxic drugs. In general, current TRP ligands identified from
the natural product realm display only modest affinity. On the
other hand, different expression levels of some TRP channels
between healthy and diseased cells may be regarded as an
opportunity to develop multiple TRP-centred drug discovery
programs. Nonetheless, engagement of TRP channels on healthy
tissues will result in toxicity as recently demonstrated with
()-englerin A. Thus, while modulators may be properly validated
as probes, pharmacodynamic/pharmacokinetic issues can
preclude their development into efficacious drugs.
It has been realized that TRPV1/2 channels may mediate cell
entry of charged small molecules. The outreach of such findings
may significantly impact on cancer research and go well beyond
simple stoichiometric combinations of TRP ligands and small
molecules of interest. Thus, one may envisage taking advantage
of TRPV biology and build capsaicin-drug conjugates for the
pharmacodelivery of cytotoxic payloads.
In summary, target deorphanisation of natural products as TRP
ligands will continuously leverage understanding of this emerging
family of ion channels in diseases, while providing innovative
scaffolds for groundbreaking chemical biology and drug discovery.
Henceforth, natural products, their derivatives and TRP-directed
drug delivery constructs may yield an original means of tackling
cancers with potential application in translational medicine, e.g. as
chemotherapeutics and probes for fluorescence-guided surgery.
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